IP Library Granted Patent US 9,492,419
Granted Patent B2
US 9,492,419 · App. 14/680,547 · Granted Nov 15, 2016

Method for treating crohn'S disease or ulcerative colitis by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain

Inventors: Elazar Rabbani (New York, NY); Xiaofeng Li (Farmington, CT); Dakai Liu (South Setauket, NY); Yazhou Zhang (South Setauket, NY); Richard Jin (Pennington, NJ); Riddhi Bhattacharyya (West Babylon, NY); Wei Cheng (Valley Stream, NY); James J. Donegan (Long Beach, NY)
Assignee: Enzo Biochem, Inc.
A61K31/235A61K31/015A61K31/185A61K31/192A61K31/395A61K31/535G01N33/5011G01N33/5041G01N33/564G01N33/92A61K38/00G01N2333/705G01N2800/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,492,419
App. No.
14/680,547
Granted
Nov 15, 2016
Kind
B2
Abstract

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

Claims (10)

1. A method for treating Crohn's disease or ulcerative colitis, comprising:

administering to a human patient having Crohn's disease or ulcerative colitis a therapeutically effective amount of a compound selected from the group consisting of:

2. The method of claim 1 , wherein the human patient has Crohn's disease.

3. The method of claim 1 , wherein the human patient has ulcerative colitis.

4. The method of claim 2 , wherein the compound is

5. The method of claim 2 , wherein the compound is

6. The method of claim 2 , wherein the compound is

7. The method of claim 3 , wherein the compound is

8. The method of claim 3 , wherein the compound is

9. The method of claim 3 , Wherein the compound is

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2016
From: LI, XIAOFENG; JIN, RICHARD; CHENG, WEI; RABBANI, ELAZAR; DONEGAN, JAME J.; BHATTACHARYYA, RIDDHI; LIU, DAKAI; ZHANG, YAZHOU
To: ENZO BIOCHEM, INC.
Reel/Frame 039866/0441 →
Continuity (7)
Division 12221863 · Aug 7, 2008
Continuation In Part 11598916 · Nov 14, 2006
Continuation In Part 11097518 · Apr 1, 2005
Continuation In Part 11084668 · Mar 18, 2005
Continuation In Part 10849067 · May 19, 2004
Provisional Application 60504860 · Sep 22, 2003
Related Publication 20150216832A1 · Aug 6, 2015